Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Anti-NKG2D (NN8555) (formerly IPH 2301)
Also known as: NNC 0142-0000-0002
print preview
bookmark
share with colleague
General Information
Company
Innate Pharma S.A.
Description
Recombinant human mAb targeting natural killer (NK) and T cells
Molecular Target
Natural killer T cells
Mechanism of Action
Antibody
Latest Stage of Development
Phase II
Indication
Rheumatoid arthritis (RA)
Partner
Novo Nordisk A/S
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy